uniQure (NASDAQ:QURE) Upgraded at StockNews.com

StockNews.com upgraded shares of uniQure (NASDAQ:QURE) to a sell rating in a report released on Wednesday morning.

A number of other equities research analysts also recently weighed in on QURE. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of uniQure in a report on Tuesday. Cantor Fitzgerald lifted their target price on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $20.00 to $52.00 in a report on Tuesday. Royal Bank of Canada decreased their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group dropped their price objective on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, uniQure has an average rating of “Moderate Buy” and an average target price of $32.14.

uniQure Trading Up 2.3 %

QURE stock opened at $15.40 on Wednesday. uniQure has a 52 week low of $3.73 and a 52 week high of $17.39. The company has a market capitalization of $750.60 million, a PE ratio of -3.10 and a beta of 0.89. The company’s 50-day simple moving average is $6.85 and its 200 day simple moving average is $6.28. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. As a group, sell-side analysts anticipate that uniQure will post -3.81 earnings per share for the current year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. increased its stake in shares of uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares in the last quarter. Walleye Capital LLC acquired a new stake in uniQure in the third quarter worth $444,000. Vanguard Group Inc. grew its holdings in uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after purchasing an additional 109,740 shares during the period. Assenagon Asset Management S.A. increased its stake in uniQure by 49.1% in the third quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 89,400 shares in the last quarter. Finally, Privium Fund Management B.V. raised its holdings in shares of uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after purchasing an additional 104,500 shares during the period. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.